MTD Mettler Toledo International Inc/ (MTD) Insider Trading, Ownership & Congress Trades
Medical Devices · Laboratory analytical instruments · CIK 0001037646
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
335
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · $2.8M priced
What the filings say about MTD
Insiders, 180 days
-$6.1M net sold
4 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
0 bought · 1 sold
Latest: sale, 2025-12-08
Planned sales (Form 144), 90 days
$1.2M
2 notices
Mettler Toledo International Inc/ insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, METTLER TOLEDO INTERNATIONAL INC/ insiders sold a net $6.1M of stock across 496 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Nov 12, 2025.
- The trade is 21.0% of the 4,480 shares held after it.
- 3 other insiders sold within 30 days.
- 335 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Kaltenbach Patrick sold about $1.3M of MTD on Aug 27, 2026; 3 other insiders sold within 30 days and 335 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Aug 3, 2026.
- The trade is 142.8% of the 292 shares held after it.
- 3 other insiders sold within 30 days.
- 335 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SALICE THOMAS P sold about $600.7K of MTD on Aug 5, 2026; 3 other insiders sold within 30 days and 335 funds added in the latest 13F quarter.Context
- 29 earlier Form 4 trades (code P or S) here by this insider (29 sales), the last on Feb 10, 2026.
- The trade is 40.2% of the 5,579 shares held after it.
- 3 other insiders sold within 30 days.
- 335 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Vadala Shawn sold about $3.2M of MTD on Aug 3, 2026; 3 other insiders sold within 30 days and 335 funds added in the latest 13F quarter.Context
- 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Nov 21, 2025.
- The trade is 92.7% of the 259 shares held after it.
- 3 other insiders sold within 30 days.
- 335 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Head of Process Analytics Keller Gerry sold about $342.5K of MTD on Aug 3, 2026; 3 other insiders sold within 30 days and 335 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Aug 13, 2025.
- The trade is 142.1% of the 292 shares held after it.
- 3 other insiders sold within 30 days.
- 335 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SALICE THOMAS P sold about $599.5K of MTD on Aug 3, 2026; 3 other insiders sold within 30 days and 335 funds added in the latest 13F quarter.496 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$6.1M over 180 days
-$6.1M over 90 days
below 79% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
335 funds bought in last quarter
more than 90% of Medical Devices
Revenue
+4.0% year over year
below 68% of Medical Devices
Margin
21.6% net margin
more than 94% of Medical Devices
Buybacks
$412.5M repurchased, FY to 2026-06-30
more than 83% of Medical Devices
Short interest
3.6% of the float short (float per yahoo 2026-10-26) · 2.8 days to cover · settled 2026-09-30
more than 51% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch MTD
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+20.9%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MTD: institutional holders (13F)
13F holdings, latest reported quarter
1,882,344 sh
$2.4B
1,521,543 sh
$1.9B
1,319,636 sh
$1.7B
1,010,490 sh
$1.3B
951,679 sh
$1.2B
Congress trades in MTD
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-12-08 · disclosed 36 days later
$1,001 - $15,000
Bought 2025-07-25 · disclosed 172 days later
$1,001 - $15,000
Bought 2025-05-15 · disclosed 16 days later
$1,001 - $15,000
Sold 2025-04-08 · disclosed 20 days later
$1,001 - $15,000
Sold 2025-04-01 · disclosed 43 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
MTD planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Thomas Salice
Filed 2026-08-05
$600.7K
Thomas Salice
Filed 2026-08-03
$599.5K
Michael Kelly
Filed 2026-07-28
$1.2M
MTD mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Baron Health Care Fund
$6.4M position · as of 2026-06-30
5.6%
PAPP SMALL & MID-CAP GROWTH FUND
$2.0M position · as of 2026-05-31
5.0%
Virtus KAR Health Sciences Fund
$3.7M position · as of 2026-06-30
4.0%
iShares Health Innovation Active ETF
$388.1K position · as of 2026-07-31
3.5%
NYLIM PineStone U.S. Equity Fund
$12.5M position · as of 2026-07-31
3.3%
BARON ASSET FUND
$120.9M position · as of 2026-06-30
3.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · PEO1
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$6.9M
$6.5M
$1.6M
+7%
+2%
2023
$8.5M
$4.7M
$1.4M
+6%
+3%
2022
$6.5M
$4.6M
$1.5M
+27%
+9%
2020
$6.5M
$17.9M
$1.7M
+44%
+40%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $6.1M sold by insiders over 180 days, 335 funds added last quarter, $1.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
MTD financials
Revenue growth
+4.0%
XBRL, annual
Net margin
21.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.1B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM MTD
| FY Dec 2025 | $4.0B |
| FY Dec 2024 | $3.9B |
| FY Dec 2023 | $3.8B |
| FY Dec 2022 | $3.9B |
| FY Dec 2021 | $3.7B |
| Jun 2026 | $1.0B |
| Mar 2026 | $947.1M |
| Dec 2025 | $1.1B |
| Sep 2025 | $1.0B |
| Jun 2025 | $983.2M |
| Mar 2025 | $883.7M |
| Dec 2024 | $1.0B |
| Sep 2024 | $954.5M |
At each fiscal year end
Single quarter
Net margin, TTM
+21.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM MTD
| FY Dec 2025 | +21.6% |
| FY Dec 2024 | +22.3% |
| FY Dec 2023 | +20.8% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +22.7% |
| Mar 2026 | +17.9% |
| Dec 2025 | +25.3% |
| Sep 2025 | +21.1% |
| Jun 2025 | +20.6% |
| Mar 2025 | +18.5% |
| Dec 2024 | +24.1% |
| Sep 2024 | +22.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$864.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM MTD
| FY Dec 2025 | $848.6M |
| FY Dec 2024 | $864.4M |
| FY Dec 2023 | $860.6M |
| FY Dec 2022 | $737.8M |
| FY Dec 2021 | $801.2M |
| Jun 2026 | $282.6M |
| Mar 2026 | $122.4M |
| Dec 2025 | $184.1M |
| Sep 2025 | $274.9M |
| Jun 2025 | $212.5M |
| Mar 2025 | $177.2M |
| Dec 2024 | $224.9M |
| Sep 2024 | $233.2M |
At each fiscal year end
Single quarter
Debt to equity
164.70x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity MTD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 81.25x |
| FY Dec 2021 | 9.81x |
| Jun 2026 | 164.70x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.46x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt MTD
| FY Dec 2025 | 0.44x |
| FY Dec 2024 | 0.48x |
| FY Dec 2023 | 0.46x |
| FY Dec 2022 | 0.43x |
| FY Dec 2021 | 0.54x |
| Jun 2026 | 0.46x |
| Mar 2026 | 0.40x |
| Dec 2025 | 0.44x |
| Sep 2025 | 0.45x |
| Jun 2025 | 0.44x |
| Mar 2025 | 0.47x |
| Dec 2024 | 0.48x |
| Sep 2024 | 0.47x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity MTD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+25.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets MTD
| FY Dec 2025 | +25.0% |
| FY Dec 2024 | +26.2% |
| FY Dec 2023 | +23.0% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +25.6% |
| Mar 2026 | +25.4% |
| Dec 2025 | +25.0% |
| Sep 2025 | +24.4% |
| Jun 2025 | +25.0% |
| Mar 2025 | +26.1% |
| Dec 2024 | +26.2% |
| Sep 2024 | +24.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital MTD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed MTD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
37.64x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing MTD
| FY Dec 2025 | 33.14x |
| FY Dec 2024 | 30.21x |
| FY Dec 2023 | 33.79x |
| FY Dec 2022 | 37.61x |
| FY Dec 2021 | 51.74x |
| Jun 2026 | 28.79x |
| Mar 2026 | 29.61x |
| Dec 2025 | 33.14x |
| Sep 2025 | 30.64x |
| Jun 2025 | 29.77x |
| Mar 2025 | 29.47x |
| Dec 2024 | 30.21x |
| Sep 2024 | 40.42x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$35.5B
market value at close 2026-10-23 on 2026-06-30 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value MTD
| FY Dec 2025 | $30.6B |
| FY Dec 2024 | $28.1B |
| FY Dec 2023 | $28.7B |
| FY Dec 2022 | $34.1B |
| FY Dec 2021 | $40.6B |
| Jun 2026 | $27.7B |
| Mar 2026 | $27.6B |
| Dec 2025 | $30.6B |
| Sep 2025 | $27.2B |
| Jun 2025 | $26.3B |
| Mar 2025 | $26.6B |
| Dec 2024 | $28.1B |
| Sep 2024 | $34.0B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+2.6%
TTM free cash flow over market value at close 2026-10-23
FCF yield MTD
| FY Dec 2025 | +3.0% |
| FY Dec 2024 | +3.3% |
| FY Dec 2023 | +3.2% |
| FY Dec 2022 | +2.3% |
| FY Dec 2021 | +2.1% |
| Jun 2026 | +3.4% |
| Mar 2026 | +3.1% |
| Dec 2025 | +3.0% |
| Sep 2025 | +3.5% |
| Jun 2025 | +3.5% |
| Mar 2025 | +3.5% |
| Dec 2024 | +3.3% |
| Sep 2024 | +2.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
3.02x
P/E over trailing EPS growth of 12%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing MTD
| FY Dec 2025 | 8.55x |
| FY Dec 2024 | 2.36x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 2.19x |
| FY Dec 2021 | 1.65x |
| Jun 2026 | 2.31x |
| Mar 2026 | 4.71x |
| Dec 2025 | 8.55x |
| Sep 2025 | 3.83x |
| Jun 2025 | 3.48x |
| Mar 2025 | 2.39x |
| Dec 2024 | 2.36x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $4.0B | $3.9B | $3.8B | $3.9B |
| Gross profit | $2.4B | $2.3B | $2.2B | $2.3B |
| Net income | $869.2M | $863.1M | $788.8M | $872.5M |
| EPS (diluted) | 42.05 | 40.48 | 35.90 | 38.41 |
| Operating cash flow | $955.8M | $968.3M | $965.9M | $859.1M |
| Cash | $66.9M | $59.4M | $69.8M | $96.0M |
| Long-term debt | $2.1B | $1.8B | $1.9B | $1.9B |
| Buybacks | $800.0M | $850.0M | $900.0M | $1.1B |
SEC XBRL, fiscal years, as known on 2026-10-27
MTD Stock Sonar score 5/7 axes
Find similar shapesCompareMTD ranks highest on risk and compliance (64th percentile) and institutional and government (50th), and lowest on insider conviction (9th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MTD filings, in plain words
Are Mettler Toledo International Inc/ insiders buying or selling MTD?
In the 180 days to 2026-10-27, Mettler Toledo International Inc/ insiders were net sellers, a net $6.1M across purchases and sales reported on Form 4, by 4 sellers.
Have members of Congress traded MTD?
Yes. In the year to 2026-10-27, 0 House members disclosed buying MTD and 1 House member disclosed selling it; the latest on record is a sale by Julia Letlow dated 2025-12-08.
Are there planned insider sales of MTD?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $1.2M of stock; the latest, by Thomas Salice, was filed 2026-08-05.
Read the full summary
In the 180 days to 2026-10-27, Mettler Toledo International Inc/ insiders were net sellers of MTD, a net $6.1M across purchases and sales reported on Form 4 by 4 sellers. None of the 5 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-27, 0 members of Congress disclosed buying MTD and 1 member disclosed selling it; the latest on record is a sale by Julia Letlow dated 2025-12-08. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $1.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
